Interferons and bladder cancer

被引：6

作者：

Brown, DH ^{[1
]}

Wagner, TT ^{[1
]}

Bahnson, RR ^{[1
]}

机构：

[1] Ohio State Univ, Div Urol, Columbus, OH 43210 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2000年 / 27卷 / 01期

关键词：

D O I：

10.1016/S0094-0143(05)70245-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

With the introduction of BCG, intravesical instillation of immunotherapeutic agents has become a mainstay of therapy in the treatment of superficial bladder cancer. Interferon is capable of inducing a non-specific cellular and humoral immune response towards tumor cells. It has shown promise in reducing the recurrence and progression rates of superficial bladder cancer, in contrast to BCG, intravesical interferon is associated with minimal side effects and a very low dropout rate. Current research has focused on the use of interferon in combination with immunotherapeutic and cytotoxic drugs.

引用

页码：171 / +

页数：9

共 45 条

[1] EFFECTS OF INTERFERON IN COMBINATION WITH CYTO-TOXIC DRUGS ON MOUSE BLADDER-TUMOR (MBT-2) GROWTH-INVITRO AND INVIVO [J].